RSV/hMPV vaccine candidate Dose L

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Past

days

SNYPhase 2$115.3B

RSV/hMPV vaccine candidate Dose L Phase 2 Results Expected

RSV/hMPV vaccine candidate Dose L• Respiratory Syncytial Virus Infection646

Mar 10Estimated

00%

Competitive Landscape

1 competitor in Respiratory Syncytial Virus Infection

Drug Information

Target Indication

Respiratory Syncytial Virus Infection

Clinical Trial

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Influenza (Healthy Volunteers)

Type 2 Diabetes Mellitus

Diphtheria

Non Small Cell Lung Cancer

Influenza